C-Reactive Protein (CRP) Gene Variants and Coronary Artery Disease in a Chinese Han Population

Coronary Artery Disease Clinical Trial

— CRP-Han  

Official title:

CRP Gene Variants and Coronary Artery Disease in a Chinese Han Population

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00780221
• Other study ID #: ZSJQ-30725036
• Secondary ID: 30725036
• Status: Recruiting
• Phase: N/A
• First received: October 24, 2008
• Last updated: October 24, 2008
• Start date: October 2008
• Est. completion date: December 2010

Study information

• Verified date: October 2008
• Source: Fudan University
• Contact: Chaoneng Wu, PhD
• Phone: +86-21-64041990
• Email: wuchaoneng[@]hotmail.com
• Is FDA regulated: No
• Health authority: China: National Natural Science Foundation
• Study type: Observational

Clinical Trial Summary

The recognition of the association between circulating C-reactive protein (CRP) levels and risk of coronary heart disease (CHD) has led to an increased emphasis on CRP genetic effects on CRP level and CHD. However, the causality of CRP variants remains uncertain.The objective of this study is to evaluate the association of CRP gene variants and CRP levels in CHD in Chinese Han population. We conduct case-control study in CRP-Han study participants. The common single-nucleotide polymorphisms (SNPs) in the CRP gene, haplotypes, and plasma CRP levels are detected. A Mendelian randomization analysis will be used to help test the likelihood of causal association of gene-CRP levels, CRP levels-CHD and gene-CHD. The investigators hypothesize that CRP gene variants influence the protein level and may participate in CHD progress.

Description:

CHD patients and non-CHD population are recruited. CRP level and CHD severity by coronary angiograph will be examined. Mendelian randomization analysis are taken to analyze statically.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• clinical diagnosis of coronary artery disease

Exclusion Criteria:

• with major organ disfunction or acute inflammatory disease

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Locations

Country	Name	City	State
China	Zhongshan Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China,